Clinical Trial Update: Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year [Phase 2]

View source ↗

Summary

Open-label extended access study of lenalidomide plus dexamethasone in Chinese patients with relapsed/refractory multiple myeloma who had at least 1 year of par…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED